Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Antimicrobial Susceptibility Testing Market, By Regions
• Antimicrobial Susceptibility Testing Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Antimicrobial Susceptibility Testing Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Antimicrobial Susceptibility Testing Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Antimicrobial Susceptibility Testing Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Emergence of Multidrug Resistance Worldwide Is Expected To Drive the Antimicrobial
Susceptibility Testing Market Revenue
Resistance among various microbial species to different antimicrobial drugs have emerged as a
major cause of public health threat. According to World Health Organization (WHO), these
resistant microorganisms such as bacteria, fungi, viruses, and parasites are able to combat
attack by antimicrobial drugs, which leads to ineffective treatment resulting in persistence and
spreading of infections.
Increasing number of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza,
and others among the global population is expected to result in increasing adoption of
antimicrobial susceptibility testing to reduce the resistance exposure during the forecast period.
For instance, according to the WHO, in 2016, an estimated 490,000 people worldwide
developed MDR-TB. The countries with the largest numbers of MDR/RR-TB cases were China,
India and the Russian Federation.
Moreover, development of genotypic-based methods offering rapid and accurate detection or
confirmation of antimicrobial resistance is expected to drive the market growth. For instance,
the Accelerate ID/AST System or ID/AST System (Accelerate) aims to reduce the turnaround